Topical Cannabinoid Composition for Skin Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for skin diseases, such as eczema and psoriasis, often rely on corticosteroids and systemic medications that have significant side effects, are not targeted for itching, and lack effectiveness for conditions like epidermolysis bullosa, with oral and systemic cannabinoid administration causing psychoactive side effects due to rapid absorption.
Innovation Solution
A topical cannabinoid composition comprising a cannabinoid (0.01-10% w/w), a humectant (0.01-10% w/w), a penetration enhancer (1-5% w/w), and water, with ethanol content less than 40% w/w, designed to improve skin penetration and reduce systemic absorption, using cannabinoids like CBD and THC, and potentially combined with other agents for enhanced efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If oral or systemic cannabinoid administration is used to treat skin diseases, then therapeutic effects are achieved, but psychoactive side effects occur due to rapid systemic absorption
Solution Approach 1:
The invention segments the delivery system by using a topical formulation that targets the skin locally rather than systemic delivery. The composition includes specific penetration enhancers (1-5% w/w) and humectants (0.01-10% w/w) that facilitate localized cannabinoid delivery to skin tissues while preventing systemic absorption, thereby achieving therapeutic effects at the application site without psychoactive side effects
Solution Approach 2:
The topical cannabinoid composition provides localized therapeutic action directly at the skin disease site. The formulation is designed to remain primarily in the skin with controlled penetration, creating a high concentration gradient locally while maintaining low systemic levels. This local quality approach ensures therapeutic effectiveness for skin conditions like eczema and psoriasis without causing psychoactive effects associated with systemic cannabinoid exposure
2Productivity
If high concentration cannabinoid formulations are used to achieve rapid therapeutic effects, then treatment speed is improved, but psychoactive and central nervous system side effects increase
Solution Approach 1:
The invention changes the concentration parameters by using a controlled range of cannabinoid concentrations (0.01-10% w/w) combined with specific formulation parameters including penetration enhancers (1-5% w/w) and humectants (0.01-10% w/w). This parameter optimization allows for effective skin penetration and rapid therapeutic action while maintaining concentrations that prevent psychoactive effects and CNS side effects
3Object-affected harmful factors
If corticosteroids are used to treat skin diseases, then inflammation and itching are reduced, but negative side effects on skin immunity and adrenal glands occur
Solution Approach 1:
The invention uses cannabinoids as intermediary substances that mediate the treatment of skin diseases through a different mechanism than corticosteroids. The topical cannabinoid composition acts on cannabinoid receptors in the skin to reduce inflammation and itching without suppressing skin immunity or affecting adrenal gland function. This intermediary approach provides an alternative therapeutic pathway that avoids the harmful side effects associated with corticosteroid use
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The topical composition provides localized therapeutic effects with reduced systemic absorption, minimizing side effects and effectively treating skin diseases like eczema and psoriasis while addressing itching and inflammation, with prolonged skin residence time for improved treatment outcomes.
Implementation Method 1
a penetration enhancer at 1-5% (w/w)
Implementation Method 2
a humectant at 0.01-10% (w/w)
Data Source
AI summary
Topical compositions comprising cannabinoids in combination with one or more humectants and one or more penetration enhancers are provided. Also provided are methods comprising applying a topical cannabinoid composition provided herein to the skin of a subject and uses of a topical cannabinoid formulation provided herein for the treatment of a skin disease or condition in a subject.